Abstract
Based on keywords co-occurrence analysis, four research topics were identified: orphan drug clinical trials, postmarketing ADR surveillance for orphan drugs, rare diseases and orphan drug management, and diagnosis and treatment of rare diseases. Immune-related adverse reactions and benefit-risk assessment of enzyme replacement therapy were at the forefront of research in this field. Treatment outcomes, early diagnosis and natural history studies of rare diseases may become hotspots for future research.
Introduction
Rare diseases (RDs) affect over 350 million people worldwide, yet individual patient populations are tiny, creating a "data desert" for drug safety. Traditional randomized controlled trials (RCTs) are often unfeasible, leading to orphan drugs being approved based on smaller, non-randomized, or open-label studies. Consequently, the real safety profile of these drugs often only emerges after they hit the market. While pharmacovigilance (PV) is well-established for common medications, the unique challenges of rare diseases—such as off-label use, high costs, and lack of historical data—require a specialized approach. This paper presents the first systematic bibliometric mapping of the PV landscape for rare diseases, tracking its evolution from 1997 to 2022.
Methodology
The study utilized the Web of Science Core Collection (WoSCC), specifically the SCI-Expanded database, covering the period from January 1, 1997, to October 25, 2022. The authors employed bibliometric and knowledge-map analysis using CiteSpace 6.1.R6 to visualize patterns and trends. This computational approach included co-occurrence analysis of authors and institutions, cluster analysis of research topics, and burst detection to identify sudden shifts in research focus.
After manual filtering for relevance, the initial 1,134 results were narrowed down to 599 valid publications, consisting of 456 research articles and 143 reviews.
Results
Growth and Geographic Trends
The field has evolved through three distinct stages: a "start-up" period (1997–2009), a "fluctuation growth" period (2010–2015), and a "steady development" period (2016–present), with 2021 being the most prolific year. Geographically, the US and UK are the primary contributors. While China started later (2012), it has rapidly become the sixth most productive nation. Countries like Spain and Switzerland serve as "bridges," connecting disparate research groups globally.
Institutional and Journal Influence
The University of California and Harvard University emerged as the most productive and influential institutions. The Cochrane Database of Systematic Reviews published the most articles, while the New England Journal of Medicine held the highest co-citation frequency, marking it as a foundational source of high-quality evidence.
Research Hotspots and Frontiers
Four main research clusters were identified: orphan drug clinical trials, post-marketing surveillance, management of rare diseases/orphan drugs, and diagnosis/treatment strategies. Keyword trends show a migration from general "adverse drug reactions" to specific areas like Immune Checkpoint Inhibitors (ICIs) and Enzyme Replacement Therapy (ERT). Recent "bursts" (2018–2022) for keywords like "nivolumab" and "natural history" highlight the shift toward precision medicine and the use of historical controls in the absence of placebo groups.
Discussion and Future Directions
The research focus is increasingly moving toward the use of real-world evidence (RWE) to supplement traditional clinical trial data. The authors predict that future research will pivot toward early diagnosis and treatment outcomes.
However, the study is limited by its sole reliance on the Web of Science and English-language publications, which may introduce geographic and language biases. To overcome inherent data scarcity, the authors emphasize the need for deeper international collaboration and the integration of diverse databases to provide a more global perspective on rare disease safety.
Summary updated